Shun Ishido

Dr. Shun Ishido

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
HMHiroaki Matsumoto
Hiroaki Matsumoto
KTKaoru Tsuchiya
Kaoru Tsuchiya
HNHiroyuki Nakanishi
Hiroyuki Nakanishi
YHYuka Hayakawa
Yuka Hayakawa
YYYutaka Yasui
Yutaka Yasui
NINamiki Izumi
Namiki Izumi
Background: Sarcopenia is associated with overall survival in patients with hepatocellular carcinoma (HCC). However, it is not known whether muscle volume is associated with clinical outcomes during combination therapy with immune checkpoint inhibitors. We investigated the relationship between changes in muscle volume and treatment outcomes in patients treated with atezolizumab plus bevacizumab. Methods: Thirty-two patients with HCC who received atezolizumab plus bevacizumab as the first-line treatment between October 2020 and February 2022 were included. Skeletal muscle mass index (SMI) was calculated from the skeletal muscle area at the L3 level of the lumbar vertebrae. We compared pretreatment SMI and SMI at 6–14 weeks after administration. Results: Of the 32 patients, 18 had a decreased SMI, while 14 did not. Progression-free survival (PFS) was significantly longer in patients without SMI decrease than in patients with SMI decrease (8.5 vs. 5.8 months, p = 0.011). There were no significant differences in treatment-related adverse events between the patients with and without SMI. Presarcopenia at baseline was not significantly associated with PFS. Conclusions: Decreased SMI was significantly associated with PFS. Monitoring muscle volume during atezolizumab plus bevacizumab therapy is useful in clinical practice.

17 June 2023 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
SIShun Ishido
Shun Ishido
NTNobuharu Tamaki
Nobuharu Tamaki
YTYuka Takahashi
Yuka Takahashi
NUNaoki Uchihara
Naoki Uchihara
KSKeito Suzuki
Keito Suzuki
NINamiki Izumi
Namiki Izumi
Background: Patients with nonalcoholic fatty liver disease (NAFLD) are highly at risk for cardiovascular disease (CVD). However, the risk of developing CVD in patients with lean NAFLD is not yet fully understood. Therefore, this study aimed to compare the CVD incidence in Japanese patients with lean NAFLD and those with non-lean NAFLD. Methods: A total of 581 patients with NAFLD (219 with lean and 362 with non-lean NAFLD) were recruited. All patients underwent annual health checkups for at least 3 years, and CVD incidence was investigated during follow-up. The primary end-point was CVD incidence at 3 years. Results: The 3-year new CVD incidence rates in patients with lean and non-lean NAFLD were 2.3% and 3.9%, respectively, and there was no significant difference between two groups (p = 0.3). Multivariable analysis adjusted for age, sex, hypertension, diabetes, and lean NAFLD/non-lean NAFLD revealed that age (every 10 years) as an independent factor associated with CVD incidence with an odds ratio (OR) of 2.0 (95% confidence interval [CI]: 1.3–3.4), whereas lean NAFLD was not associated with CVD incidence (OR: 0.6; 95% CI: 0.2–1.9). Conclusions: CVD incidence was comparable between patients with lean NAFLD and those with non-lean NAFLD. Therefore, CVD prevention is needed even in patients with lean NAFLD.

24 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SIShun Ishido
Shun Ishido
KTKaoru Tsuchiya
Kaoru Tsuchiya
YKYoshihito Kano
Yoshihito Kano
YYYutaka Yasui
Yutaka Yasui
KTKenta Takaura
Kenta Takaura
NINamiki Izumi
Namiki Izumi
This study aimed to investigate the clinical usefulness of comprehensive genomic profiling (CGP) in patients with unresectable hepatocellular carcinoma who received multiple systemic therapies in real-world practice. In this study, all nine patients had gene alterations, and seven were candidates eligible for clinical trials based on the results of CGP. The median number of alterations per patient was four, and the blood sample was used in five patients with extrahepatic metastasis. We revealed the genomic information of the patients who received multiple systemic therapies and reported the utility of blood samples in patients with extrahepatic metastasis. Furthermore, the genomic status in patients treated with multiple molecular-targeted agents, including checkpoint inhibitors, would contribute to developing newer systemic agents. The molecular mechanism of hepatocellular carcinoma (HCC) is partially demonstrated. Moreover, in the patients receiving multiple molecular-targeted therapies, the gene alternations are still unknown. Six molecular-targeted therapies of unresectable HCC (uHCC) and comprehensive genomic profiling (CGP) have been approved in clinical practice. Hence, the utility of CGP in patients with uHCC treated with multiple molecular-targeted agents is investigated. The data of the patients with uHCC who received CGP tests were collected, retrospectively, between February 2021 and May 2022. Gene alterations detected by foundation testing, excluding variants of unknown significance, were reported in all nine patients. The samples for CGP were derived from liver tumor biopsy (n = 2), surgical specimens of bone metastases (n = 2), and blood (n = 5). The median number of systemic therapies was four. Seven patients were candidates eligible for clinical trials. One patient with a high tumor mutation burden (TMB) could receive pembrolizumab after CGP. This study presented genomic alternations after receiving multiple molecular-targeted therapies. However, further investigation needs to be conducted to develop personalized therapies and invent newer agents for treating HCC.

5 July 2023 in Clinical Case Reports
Verified
Journal Article
Open access
SIShun Ishido
Shun Ishido
NTNobuharu Tamaki
Nobuharu Tamaki
KIKento Inada
Kento Inada
JIJun Itakura
Jun Itakura
YTYuka Takahashi
Yuka Takahashi
NINamiki Izumi
Namiki Izumi
Key Clinical Message: The liquid CGP was useful for detecting FGFR2 fusion and the patient experienced typical side effects (nail disorders, hyperphosphatemia, and taste disorders) of pemigatinib that required treatment.

29 May 2023 in JGH Open
Verified
Journal Article
Open access
SIShun Ishido
Shun Ishido
NTNobuharu Tamaki
Nobuharu Tamaki
MKMasayuki Kurosaki
Masayuki Kurosaki
NMNami Mori
Nami Mori
KTKeiji Tsuji
Keiji Tsuji
NINamiki Izumi
Namiki Izumi
Background and Aim: Hepatocellular carcinoma (HCC) surveillance in low‐risk patients (annual incidence <1.5%) is not recommended per the American Association for the Study of Liver Diseases guidelines. Because patients with chronic hepatitis C with non‐advanced fibrosis who have achieved sustained virological response (SVR) have a low risk of HCC, HCC surveillance is not recommended for them. However, aging is a risk factor for HCC; threfore, the necessity for HCC surveillance in older patients with non‐advanced fibrosis needs to be verified.Methods: This multicenter, prospective study enrolled 4993 patients with SVR (1998 patients with advanced fibrosis and 2995 patients with non‐advanced fibrosis). The HCC incidence was examined with particular attention to age.Results: The 3‐year incidence of HCC in patients with advanced and non‐advanced fibrosis was 9.2% (95% CI: 7.8–10.9) and 2.9% (95% CI: 2.1–3.7), respectively. HCC incidence was significantly higher in patients with advanced fibrosis (P < 0.001). HCC incidence stratified by age and sex was investigated in patients with non‐advanced fibrosis. The HCC incidence in the 18–49, 50s, 60s, 70s, and ≥80 age groups were 0.26, 1.3, 1.8, 1.7, and 2.9 per 100 person‐years in men, and 0.00, 0.32, 0.58, 0.49, and 0.57 per 100 person‐years in women, respectively.Conclusions: Male patients with non‐advanced fibrosis aged ≥60 years have a higher risk of developing HCC and, thus, require HCC surveillance.

21 July 2023 in JGH Open
Verified
Journal Article
Open access
SIShun Ishido
Shun Ishido
NTNobuharu Tamaki
Nobuharu Tamaki
NUNaoki Uchihara
Naoki Uchihara
KSKeito Suzuki
Keito Suzuki
YTYuki Tanaka
Yuki Tanaka
NINamiki Izumi
Namiki Izumi
Background and Aim: Hepatocellular carcinoma development can be decreased by achieving and maintaining complete virological response (CVR) in chronic hepatitis B. However, it is unclear whether switching from entecavir (ETV) to tenofovir alafenamide (TAF) could achieve and maintain CVR in patients with low‐level viremia (LLV; HBV DNA ≤ 3.3 log IU/mL) or occasional detectable HBV DNA during ETV treatment. Therefore, we aimed to examine whether the switching from ETV to TAF is effective in achieving CVR in patients with LLV or occasional detectable HBV DNA.Methods: This study comprised 45 patients who switched from ETV to TAF. All patients received ETV and TAF for >2 years, and the HBV DNA levels were measured every 3 months. Maintaining undetectable HBV DNA during 2‐year period is defined as CVR. The primary endpoint is the CVR rate during ETV and TAF treatment.Results: The CVR rate for each of the 2 years of ETV and TAF therapy was 33.3% (15/45) and 68.9% (31/45, P < 0.01), respectively, and the CVR rate increased by switching from ETV to TAF. In patients with occasional detectable HBV DNA during ETV treatment (22 patients), 15 achieved CVR and 7 maintained occasional detectable HBV DNA. In patients with LLV during ETV treatment (eight patients), three achieved CVR and five had occasional detectable HBV DNA.Conclusion: Switching from ETV to TAF increases the CVR rate in patients with LLV or occasional detectable HBV DNA and could be an alternative treatment option.